Guessous I, Rodondi N, Paccaud F
Institut universitaire de médecine sociale et préventive IUMSP, Unité d'evaluation des soins UES, Rue du Bugnon 17, 1005 Lausanne.
Rev Med Suisse. 2005 Oct 26;1(38):2447-8, 2451-2.
Making statin available over the counter is one of the measures proposed to correct its underuse. Since May 2004, simvastatin 10 mg is sold over the counter in Great Britain. But uncertainties persist concerning the efficacy of statin in primary prevention and at a 10 mg dose. Finally, there is a risk of side effects and drug interactions. Beyond the correction of statin underuse and the hope of coronary heart disease mortality reduction, the British decision highlighted the will to give individuals a sense of responsibility concerning their health and its financial cost. Anyway, the benefit of switching statin from prescription to over the counter should be experimentally evaluated before its introduction.
将他汀类药物非处方销售是为纠正其使用不足而提出的措施之一。自2004年5月起，10毫克的辛伐他汀在英国可非处方销售。但他汀类药物在一级预防中的疗效以及10毫克剂量的疗效仍存在不确定性。最后，还存在副作用和药物相互作用的风险。除了纠正他汀类药物使用不足以及降低冠心病死亡率的希望之外，英国的这一决定凸显了让个人对自身健康及其经济成本承担责任的意愿。无论如何，在将他汀类药物从处方改为非处方销售之前，应通过实验评估其益处。
